Abstract
Overview
Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments.
Commercial arrangement
There is a simple discount patient access scheme for ivosidenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact medical.information-uk@servier.com for details.
Guidance development process
Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments.
Commercial arrangement
There is a simple discount patient access scheme for ivosidenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact medical.information-uk@servier.com for details.
Guidance development process
| Original language | English |
|---|---|
| Publisher | National Institute for Health and Care Excellence (NICE) |
| Number of pages | 20 |
| ISBN (Electronic) | 978-1-4731-5698-2 |
| Publication status | Published - 31 Jan 2024 |